Molecular Analysis of Immunoglobulin Genes in Multiple Myeloma

References

• Epstein J., Xiao H., He X. Y. Markers of multiple hematopoietic stem cell lineages in multiple myeloma. New England Journal of Medicine 1990; 322: 664–668
   PubMed Web of Science ®Google Scholar
• Teoh G., Anderson K. C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematology Oncology Clinics of North America 1997; 11(1)27–42
   PubMed Web of Science ®Google Scholar
• Rettig M. A., Ma H. J., Vescio R. A., Pôld M., Schiller G., Belson D., Savage A., Nishikubo C., Wu C., Fraser J., Said I. W., Berenson J. R. Kaposi's sarcoma‐associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276: 1851–1854
   PubMed Web of Science ®Google Scholar
• van Noesel C. J. M., van Lier R. A. W. Architecture of the human B‐cell antigen receptors. Blood 1993; 82: 363–373
   PubMed Web of Science ®Google Scholar
• Chuchana P., Blancer A., Brockly E., Alexandre D., Lefranc G., Lefranc M. P. Definition of the human immunoglobulin variable lambda gene subgroups. European Journal of Immunology 1990; 20: 1317–1325
   PubMed Web of Science ®Google Scholar
• Walter M. A., Surti U., Hofker M. H., Cox D. W. The physical organization of the human immunoglobulin heavy chain gene. EMBO Journal 1990; 9: 3303–3313
   PubMed Web of Science ®Google Scholar
• Klein R., Jaenichen R., Zachau H. G. Expressed human immunoglobulin K genes and their hypermutation. European Journal of Immunology 1993; 23: 3248–3271
   PubMed Web of Science ®Google Scholar
• Korsmeyer S. J., Hieter P. A., Ravetch J. V., Poplack D. G., Waldmann T. A., Leder P. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre‐B‐cells. Proceedings of the National Academy of Sciences of the United States of America 1981; 78: 7096–7100
   PubMed Web of Science ®Google Scholar
• Reth M., Petrac E., Wiese P., Lobel L., Alt F. W. Activation of VK gene rearrangement in pre‐B cells follows the expression of membrane‐bound immunoglobulin heavy chains. EMBO Journal 1987; 6: 3299–3305
   PubMed Web of Science ®Google Scholar
• Takemori T., Rajewsky K. Lambda chain expression at different stages of ontogeny in C57BL/6, BALB/c and SJL mice. European Journal of Immunology 1981; 11: 18–625
   PubMed Web of Science ®Google Scholar
• Ehlich A., Schaal S., Gu H., Kitamura D., Muller W., Rajewsky K. Immunoglobulin heavy and light chain genes rearrange independently at early stages of B‐cell development. Cell 1993; 72: 695–704
   PubMed Web of Science ®Google Scholar
• Pauza M. E., Rehmann J. A., LeBien T. W. Unusual patterns of immunoglobulin gene rearrangement and expression during human B‐cell ontogeny: Human B‐cells can simultaneously express cell surface K and λ light chains. Journal Experimental of Medicine 1993; 178: 139–149
   PubMed Web of Science ®Google Scholar
• Nossal G. J. V. Negative selection of lymphocytes. Cell 1994; 76: 229–239
   PubMed Web of Science ®Google Scholar
• Billadeau D., Ahman G., Greipp P., Van Ness B. The bone marrow of multiple myeloma patients contains B‐cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. Journal of Experimental Medicine 1993; 178: 1023–1031
   PubMed Web of Science ®Google Scholar
• Corradini P., Boccadoro M., Voena C., Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cp sequence in immunoglobulin (IgG)‐and IgA‐secreting multiple myelomas. Journal of Experimental Medicine 1993; 178: 1091–1096
   PubMed Web of Science ®Google Scholar
• Bakkus M. H. C., Van Riet I., Van Camp B., Thiele‐mans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre‐switched but somatically mutated B cell. British Journal of Haematology 1994; 87: 68–74
   PubMed Web of Science ®Google Scholar
• Kubagawa H., Vogler L. B., Capra J. D., Conrad M. E., Lawton A. R., Cooper M. D. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the ontogenic event to its earliest point of expression in B‐cell differentiation. Journal of Experimental Medicine 1979; 150: 792–807
   PubMed Web of Science ®Google Scholar
• Bast E. J.E. G., van Camp B., Reynaert P., Wieringa G., Ballieux R. E. Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clinical and Experimental Immunology 1982; 47: 677–682
   PubMed Web of Science ®Google Scholar
• Gray D. Immunological memory. Annual Review of Immunology 1993; 11: 49–77
   PubMed Web of Science ®Google Scholar
• Bergsagel P. L., Chesi M., Nardini E., Brents L. A., Kirby S. L., Kuehl W. M. Promiscuous translocations into immunoglobulin heavy chain switc regions in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 13931–13936
   PubMed Web of Science ®Google Scholar
• Vescio R. A., Cao J., Hong C. H., Lee J. C., Wu C. H., Der‐Danielian M., Wu V., Newman R., Lichtenstein A. K., Berenson J. R. Myeloma lg heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity. Journal of Immunology 1995; 155: 2487–2497
   PubMed Web of Science ®Google Scholar
• Kosmas C., Stamatopoulos K., Loukopoulos D. Antigen selection of multiple myeloma clonogenic B cells as evidenced by VHand VL gene mutations. Blood 1997; 90: 1334–1335
   PubMed Web of Science ®Google Scholar
• Allen D., Simon T., Sablitzky E., Rajewsky K., Cumano A. Antibody engineering for the analysis of affinity maturation of an anti‐hapten response. EMBO Journal 1988; 7: 1995–2001
   PubMed Web of Science ®Google Scholar
• Sahota S. S., Leo R., Hamblin T. J., Stevenson F. K. lg VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood 1996; 87: 746–755
   PubMed Web of Science ®Google Scholar
• Kanzler H., Küppers R., Hansmann M. ‐L., Rajewsky K. Hodgkin's and Reed‐Stemberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. Journal of Experimental Medicine 1996; 184: 1495–1505
   PubMed Web of Science ®Google Scholar
• Rettig M. A., Vescio R. A., Cao J., Wu C. H., Lee J. C., Han E., Der Danielian M., Newman R., Hong C., Lichtenstein A. K., Berenson J. R. VH gene usage in multiple myeloma: complete abscence of the VH4.21 (VH4–34) gene. Blood 1996; 87: 2846–2852
   PubMed Web of Science ®Google Scholar
• Deane M., Baker B. W., Norton J. D. Immunoglobulin VH4 gene usage in B lymphoid leukaemias. British Journal of Haematology. 1993; 84: 242–249
   PubMed Web of Science ®Google Scholar
• Pritsch O., Magnac C., Dumas G., Egile C., Dighiero G. V gene usage by seven hybrids derived from CD5+ B‐cell chronic lymphocytic leukemia and displaying autoantibody activity. Blood 1993; 82: 3103–3112
   PubMed Web of Science ®Google Scholar
• Maloum K., Magnac C., Pritsch O., Binet J. L., Merle‐Béral H., Dighiero G. Skewed rearrangement of the VH4–21 gene during pre‐B acute lymphoblastic leukemia. Leukemia and Lymphoma 1995; 17: 435–441
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Levy R. Preferential use of the VH4 lg gene family by diffuse large‐cell lymphoma. Blood 1995; 86: 3072–3082
   PubMed Web of Science ®Google Scholar
• Pascual V., Victor K., Spellerberg M., Hamblin T. J., Stevenson F. K., Capra J. D. VH restriction among human cold agglutinins. The VH4–21 gene segment is required to encode anti‐I and anti‐i specificities. Journal of Immunology 1992; 149: 2337–2344
   PubMed Web of Science ®Google Scholar
• Kosmas C., Viniou N. A., Stamatopoulos K., Courte‐nay‐Luck N. S., Papadaki T., Kollia P., Paterakis G., Anag‐nostou D., Yataganas X., Loukopoulos D. Analysis of k light chain variable region in multiple myeloma. British Journal of Haematology 1996; 94: 306–317
   PubMed Web of Science ®Google Scholar
• Wagner S. D., Martinelli V., Luzzatto L. Similar patterns of VK gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 1994; 83: 3647–3653
   PubMed Web of Science ®Google Scholar
• Cannell P. K., Amlot P., Attard M., Hoffbrand A. V., Foroni L. Variable k gene rearrangement in lymphop‐roliferative disorders and analysis of VK gene usage, VJ joining and somatic mutation. Leukemia 1994; 8: 1139–1145
   PubMed Web of Science ®Google Scholar
• Sahota S. S., Leo R., Hamblin T. J., Stevenson F. K. Myeloma VL and VH sequences reveal a complementary imprint of antigen selection in tumor cells. Blood 1997; 89: 219–226
   PubMed Web of Science ®Google Scholar
• Cuisinier A. M., Fumoux D., Moinier D., Boubli L., Guigou V., Milili M., Schiff C., Fougereau M., Tonelle C. Rapid expansion of human immunoglobulin repertoire (VH, VK, Vλ) expressed in early fetal bone marrow. New Biologist 1990; 2: 689–699
   PubMedGoogle Scholar
• Rassenti L. Z., Pratt L. E., Chen P. P., Carson D. A., Kipps T. J. Autoantibody‐encoding K L chain genes frequently rearranged in λ L chain‐expressing chronic lymphocytic leukemia. Journal of Immunology 1991; 147: 1060–1066
   PubMed Web of Science ®Google Scholar
• Kosmas C., Stamatopoulos K., Papadaki T., Belessi C., Yataganas X., Anagnostou D., Loukopoulos D. Somatic hypermutation of immunoglobulin genes: focus on follicular lymphoma and multiple myeloma. Immunological Reviews 1998; 162: 281–292
   PubMed Web of Science ®Google Scholar
• Stiernholm N. B. J., Kuzniar B., Berinstein N. L. Identification of a new human Vλ gene family‐VλX. Journal of Immunology 1994; 152: 4969–4975
   PubMed Web of Science ®Google Scholar
• Boudinot P., Drapier A. ‐M., Cazenave P. ‐A., Sanchez P. Mechanistic and selective constraints act on the establishement of VλJλ junctions in the B cell repertoire. Journal of Immunology 1994; 152: 2248–2255
   PubMed Web of Science ®Google Scholar
• Betz A. G., Rada C., Pannell R., Milstein C., Neu‐berger M. S. Passenger transgenes reveal intrinsic specificity of the antibody hypermutation mechanism: clustering, polarity, and specific hot spots. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 2385–2388
   PubMed Web of Science ®Google Scholar
• Siminovitch K. A., Bakhshi A., Goldman P., Korsmeyer S. J. A uniform deleting element mediates the loss of kappa genes in human B cells. Nature 1985; 316: 260–262
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K., Kosmas C., Papadaki T., Pouliou E., Belessi C., Afendaki S., Anagnostou D., Loukopoulos D. Follicular lymphoma immunoglobulin λ light chains are affected by the antigen selection process, but to a lesser degree than their partner heavy chains. British Journal of Haematology 1997; 96: 132–146
   PubMed Web of Science ®Google Scholar
• Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996; 381: 751–758
   PubMed Web of Science ®Google Scholar
• Berek C., Milstein C. Mutation drift and repertoire shift in the maturation of the immune response. Immunological Reviews 1987; 96: 23–41
   PubMed Web of Science ®Google Scholar
• Berek C., Berger A., Apel M. Maturation of immune responses in germinal centers. Cell 1991; 67: 1121–1129
   PubMed Web of Science ®Google Scholar
• Siekevitz M., Kocks C., Rajewsky K., Dildrop R. Analysis of somatic mutation and class switching in naive and memory B cells generating adoptive primary and secondary responses. Cell 1987; 48: 757–770
   PubMed Web of Science ®Google Scholar
• Vescio R., Hong C. H., Cao J., Kim A., Schiller G. J., Lichtenstein A., Berenson R., Berenson J. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84: 3283–3290
   PubMed Web of Science ®Google Scholar
• Gazitt Y., Reading C. C., Hoffman R., Wickrema A., Vesole D., Jagannath S., Condino J., Lee B., Barlogie B., Tricot G. Purified CD34+Lin−Thy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86: 381–389
   PubMed Web of Science ®Google Scholar
• Kimlinger T., Witzig T. E. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma. Bone Marrow Transplantation 1997; 19: 553–556
   PubMed Web of Science ®Google Scholar
• Szczepek A. J., Bergsagel P. L., Axelsson L., Brown C. B., Belch A. R., Pilarski L. M. CD34+ cells in the blood of patients with multiple myeloma express CD 19 and lg mRNA and have patient‐specific IgH VDJ gene rearrangements. Blood 1997; 89: 1824–1833
   PubMed Web of Science ®Google Scholar
• Witzig T. E., Dhodapkar M. V., Kyle R. A., Greipp P. R. Quantification of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993; 72: 108–113
   PubMed Web of Science ®Google Scholar
• Billadeau D., Quam I., Thomas W., Kay N., Greipp P., Kyle R., Oken M. M. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818–1824
   PubMed Web of Science ®Google Scholar
• Schiller G., Vescio R., Freytes C., Spitzer G., Sahebi F., Lee M., Wu C. H., Cao J., Lee J. C., Hong C. H., Lichtenstein A., Lill M., Hall J., Berenson R., Berenson J. Transplantation of CD34+ peripheral blood progenitor cells after high‐dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390–397
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Tarella C., Bregni M., Siena S., Lombardi F., Gandola L., Caracciolo D., Stern A., Bonadonna G., Boccadoro M., Pileri M. High‐dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high‐risk multiple myeloma. Journal of Clinical Oncology 1994; 12: 503–509
   PubMed Web of Science ®Google Scholar
• Vesole D. H., Tricot G., Jagannath S., Desikan K. R., Siegel D., Dwayne B., Miller L., Cheson B., Crowley J., Barlogie B. Autotransplants in myeloma: what have we learned. Blood 1996; 88: 838–847
   PubMed Web of Science ®Google Scholar
• Corradini P., Voena C., Astolfi M., Ladetto M., Tarella C., Boccadoro M., Pileri S. High‐dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests before and after autografting. Blood 1995; 85: 1596–1602
   PubMed Web of Science ®Google Scholar
• Björkstrand B., Ljungman P., Bird J. M., Samson D., Gahrton G. Double high‐dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma. Bone Marrow Transplantation 1995; 15: 367–371
   PubMed Web of Science ®Google Scholar
• Falk R. H., Comenzo R. L., Skinner M. The systemic amyloidoses. New. England Journal of Medicine 1997; 337: 898–909
   PubMed Web of Science ®Google Scholar
• Solomon A., Frangione B., Franklin E. C. Bence Jones proteins and light chains of immunoglobulins: preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). Journal of Clinical Investigation 1982; 70: 453–460
   PubMed Web of Science ®Google Scholar
• Stevens F. J., Myatt E. A., Chang C. ‐H., Westholm F. A., Eulitz M., Weiss D. T., Murphy C., Solomon A., Schiffer M. A molecular model for self‐assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry 1995; 34: 10697–10702
   PubMed Web of Science ®Google Scholar
• Cogné M., Preud'homme J. L., Bauwens M., Touchard G., Aucouturier P. Structure of a monoclonal kappa chain of the VKiv subgroup in light chain deposition disease. Journal of Clinical Investigation 1991; 87: 2186–2190
   PubMed Web of Science ®Google Scholar
• Aucouturier P., Khamlichi A. A., Touchard G., Justabo E., Cogné M., Chauffert B., Martin F., Preud'homme J. L. Heavy chain deposition disease. New England Journal of Medicine 1993; 329: 1389–1393
   PubMed Web of Science ®Google Scholar
• Khamlichi A. A., Rocca A., Touchard G., Aucouturier P., Preud'homme J. L., Cogné M. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 1995; 86: 3655–3659
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Campbell M. J., Czerwinski D. K., Hart S., Miller R. A., Levy R. Induction of immune responses in patients with B cell lymphoma against the surface‐immunoglobulin idiotype expressed by their tumors. New England Journal of Medicine 1992; 327: 1209–1215
   PubMed Web of Science ®Google Scholar
• Hsu F. J., Engleman E. G., Levy R. Dendritic cells and their application in immunotherapeutic approaches to cancer therapy. Updates; Principles & Practice of Oncology, V. T. DeVita, S. Hellman, S. A. Rosenberg. Lippincott‐Raven, Philadelphia 1997; Vol. 11: 1–14, No 5
   Google Scholar
• Kwak L. W., Taub D. D., Duffey P. L., Bensinger W. I., Bryant E. M., Reynolds C. W., Longo D. L. Transfer of myeloma idiotype‐specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016–1020
   PubMed Web of Science ®Google Scholar
• Hawkins R. E., Zhu D., Ovecka M., Winter G., Hamblin T. J., Long A., Stevenson F. K. Idiotypic vaccination against human B‐cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single‐chain Fv personal vaccines. Blood 1994; 83: 3279–3288
   PubMed Web of Science ®Google Scholar
• Syrengelas A. D., Chen T. T., Levy R. DNA immunization induces protective immunity against B‐cell lymphoma. Nature Medicine 1996; 2: 1038–1041
   PubMed Web of Science ®Google Scholar
• Tao M. ‐H., Levy R. ldiotype/gTanulocyte‐macrophage colony stimulating factor fusion protein as a vaccine for B‐cell lymphoma. Nature 1993; 362: 755–758
   PubMed Web of Science ®Google Scholar
• Kwak L. W. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Annals of Oncology 1998; 9(Suppl. 1)41–46
   Google Scholar